S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
S&P 500   4,337.44
DOW   34,006.88
QQQ   359.61
3 Blue Chip Safe Havens to Shield Your Portfolio
New AI Stock Payouts (Ad)
Is Jet Blue's Descent Into Penny Stock Territory an Opportunity?
Are Gene Therapy Stocks The Market's Next Big Winners?
New AI Stock Payouts (Ad)
3 Stocks That Flourish In The Fall
Buy The World’s Largest IT Infrastructure Provider For Under $20
Options Trading Plan–Perfect For Beginners (Ad)
2 Must-Have Silicon Companies That Don't Make Microchips
This May Have Ended Alibaba's Winter, But Is It Time To Buy?
NASDAQ:KRON

Kronos Bio (KRON) Stock Forecast, Price & News

$1.28
-0.02 (-1.54%)
(As of 09/25/2023 ET)
Compare
Today's Range
$1.26
▼
$1.33
50-Day Range
$1.23
▼
$2.25
52-Week Range
$1.19
▼
$3.80
Volume
37,956 shs
Average Volume
296,757 shs
Market Capitalization
$74.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Kronos Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
681.3% Upside
$10.00 Price Target
Short Interest
Bearish
7.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$47,371 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.03) to ($2.25) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

796th out of 963 stocks

Pharmaceutical Preparations Industry

367th out of 447 stocks

See Top Rated MarketRank™ Stocks Here

KRON stock logo

About Kronos Bio (NASDAQ:KRON) Stock

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial; and Lanraplenib, a next-generation SYK inhibitor to treat the patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. The company was incorporated in 2017 and is headquartered in San Mateo, California.

KRON Price History

KRON Stock News Headlines

September 19, 2023 | americanbankingnews.com
Head to Head Comparison: Kronos Bio (NASDAQ:KRON) vs. GH Research (NASDAQ:GHRS)
August 17, 2023 | msn.com
Kronos Bio announces departure of CFO, Head of Corporate Development Al-Wakeel
September 26, 2023 | Legacy Research (Ad)
WARNING: Mandatory U.S. Dollar Recall is Weeks Away
If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.
August 17, 2023 | markets.businessinsider.com
Kronos Bio CFO Yasir Al-Wakeel To Step Down
August 17, 2023 | finance.yahoo.com
Kronos Bio Announces Departure of Chief Financial Officer and Head of Corporate Development
August 8, 2023 | msn.com
Kronos Bio GAAP EPS of -$0.52 misses by $0.04, revenue of $1.86M beats by $0.61M
August 8, 2023 | finance.yahoo.com
Kronos Bio, Inc. (KRON) Reports Q2 Loss, Misses Revenue Estimates
August 8, 2023 | msn.com
Kinnate Biopharma GAAP EPS of -$0.68 beats by $0.08
September 26, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
August 8, 2023 | finance.yahoo.com
Kronos Bio Reports Recent Business Progress and Second-Quarter 2023 Financial Results
July 19, 2023 | finance.yahoo.com
With 47% ownership, Kronos Bio, Inc. (NASDAQ:KRON) has piqued the interest of institutional investors
June 8, 2023 | bizjournals.com
Bob Langer and two other MIT entrepreneurs say what makes a good startup
June 6, 2023 | finance.yahoo.com
Kronos Bio Names Marc Besman, Ph.D., as Senior Vice President of Regulatory Affairs and Clinical Quality Assurance
May 18, 2023 | markets.businessinsider.com
Berenberg Bank Sticks to Their Buy Rating for Kronos Bio (KRON)
May 12, 2023 | finanznachrichten.de
Kronos Bio, Inc.: Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
May 12, 2023 | finance.yahoo.com
The past year for Kronos Bio (NASDAQ:KRON) investors has not been profitable
May 10, 2023 | msn.com
Kronos Bio: Q1 Earnings Insights
May 10, 2023 | finance.yahoo.com
Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results
April 24, 2023 | finance.yahoo.com
Kronos Bio Appoints Roger Dansey, M.D., to Board of Directors
April 18, 2023 | finance.yahoo.com
Kronos Bio, Inc. (NASDAQ:KRON) insider upped their holding by 11% earlier this year
April 18, 2023 | msn.com
HC Wainwright & Co. Reiterates Kronos Bio (KRON) Buy Recommendation
April 12, 2023 | finanznachrichten.de
Kronos Bio, Inc.: Kronos Bio Announces Changes to Board of Directors
April 11, 2023 | finance.yahoo.com
Kronos Bio Announces Changes to Board of Directors
March 16, 2023 | finanznachrichten.de
Kronos Bio, Inc.: Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
March 16, 2023 | msn.com
Sypris Solutions GAAP EPS of $0.01, revenue of $29.7M
March 15, 2023 | msn.com
Kronos Bio GAAP EPS of -$0.56 beats by $0.03
March 15, 2023 | finance.yahoo.com
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
See More Headlines
Receive KRON Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kronos Bio and its competitors with MarketBeat's FREE daily newsletter.

KRON Company Calendar

Last Earnings
8/08/2023
Today
9/25/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KRON
CUSIP
N/A
CIK
1741830
Web
kronosbio.com
Phone
650-781-5200
Fax
N/A
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+681.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.11)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-133,200,000.00
Net Margins
N/A
Pretax Margin
-3,890.34%
Return on Equity
-51.01%
Return on Assets
-41.31%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.16
Quick Ratio
10.16

Sales & Book Value

Annual Sales
$3.08 million
Price / Sales
24.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.30 per share
Price / Book
0.30

Miscellaneous

Outstanding Shares
58,317,000
Free Float
44,671,000
Market Cap
$74.65 million
Optionable
Not Optionable
Beta
1.53
12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Norbert W. Bischofberger Ph.D.Dr. Norbert W. Bischofberger Ph.D. (Age 67)
    Pres, CEO & Director
    Comp: $809.7k
  • Mr. Joshua A. Kazam (Age 46)
    Co-Founder & Director
    Comp: $40k
  • Dr. Yasir B. Al-Wakeel BCh (Age 41)
    BM, MA, CFO & Head of Corp. Devel.
    Comp: $564.7k
  • Dr. Jorge F. DiMartino M.D. (Age 59)
    Ph.D., Chief Medical Officer & Exec. VP of Clinical Devel.
    Comp: $593.68k
  • Ms. Barbara A. Kosacz J.D. (Age 65)
    COO, Sec. & Gen. Counsel
  • Dr. Christopher Dinsmore Ph.D. (Age 56)
    Chief Scientific Officer
  • Ms. Sarah Connors
    VP of Investor Relations & Corp. Communications
  • Mr. Charles Lin Ph.D.
    Sr. VP of TRN Mapping
  • Dr. Elizabeth A. Olek D.O. (Age 58)
    M.P.H., Sr. VP of Clinical Devel.
  • Ms. Allison Frisbee J.D.
    Sr. VP & Deputy Gen. Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KRON Stock - Frequently Asked Questions

Should I buy or sell Kronos Bio stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" KRON shares.
View KRON analyst ratings or view top-rated stocks.

What is Kronos Bio's stock price forecast for 2023?

3 Wall Street research analysts have issued 12 month price objectives for Kronos Bio's stock. Their KRON share price forecasts range from $7.00 to $14.00. On average, they predict the company's share price to reach $10.00 in the next year. This suggests a possible upside of 681.3% from the stock's current price.
View analysts price targets for KRON or view top-rated stocks among Wall Street analysts.

How have KRON shares performed in 2023?

Kronos Bio's stock was trading at $1.62 on January 1st, 2023. Since then, KRON shares have decreased by 21.0% and is now trading at $1.28.
View the best growth stocks for 2023 here.

When is Kronos Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our KRON earnings forecast.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) posted its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.02. The business had revenue of $1.86 million for the quarter, compared to the consensus estimate of $2.50 million.

When did Kronos Bio IPO?

(KRON) raised $175 million in an IPO on Friday, October 9th 2020. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler acted as the underwriters for the IPO.

What is Kronos Bio's stock symbol?

Kronos Bio trades on the NASDAQ under the ticker symbol "KRON."

Who are Kronos Bio's major shareholders?

Kronos Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include BVF Inc. IL (4.82%), Partners Capital Investment Group LLP (2.86%), BlackRock Inc. (2.40%), Renaissance Technologies LLC (2.05%), Acadian Asset Management LLC (1.00%) and Geode Capital Management LLC (0.68%). Insiders that own company stock include Backer Marianne De, Barbara Kosacz, Christopher Dinsmore, Elena Ridloff, Fund V LP Omega, Jakob Loven, Jorge Dimartino, Norbert W Bischofberger and Yasir B Al-Wakeel.
View institutional ownership trends.

How do I buy shares of Kronos Bio?

Shares of KRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kronos Bio's stock price today?

One share of KRON stock can currently be purchased for approximately $1.28.

How much money does Kronos Bio make?

Kronos Bio (NASDAQ:KRON) has a market capitalization of $74.65 million and generates $3.08 million in revenue each year. The company earns $-133,200,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis.

How many employees does Kronos Bio have?

The company employs 104 workers across the globe.

How can I contact Kronos Bio?

The official website for the company is kronosbio.com. The company can be reached via phone at 650-781-5200 or via email at media@kronosbio.com.

This page (NASDAQ:KRON) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -